Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.

Gennaro DanieleFrancesco RaspagliesiGiovanni ScambiaCarmela PisanoNicoletta ColomboSimona FrezziniGermana TognonGrazia ArtioliAngiolo GadducciRossella LauriaAnnamaria FerreroSaverio CinieriAndrea De CensiEnrico BredaPaolo ScolloUgo De GiorgiAndrea Alberto LissoniDionyssios KatsarosDomenica LorussoVanda SalutariSabrina Chiara CecereEleonora ZaccarelliMargherita NardinGiorgio BoganiMariagrazia DistefanoStefano GreggiMaria Carmela PiccirilloRoldano FossatiGaia GiannoneLaura ArenareCiro GalloFrancesco PerroneSandro Pignata

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)

EudraCT 2012-003043-29; NCT01706120.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
randomized controlled trial
clinical trial
radiation therapy
metastatic colorectal cancer